Foster Dykema Cabot & Partners’s Novo Nordisk NVO Stock Holding History

Foster Dykema Cabot & Partners’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$217K	Hold	4,526	–	–	0.01%	117
2026 Q1	$172K	Hold	4,526	–	–	0.01%	125
2025 Q4	$230K	Hold	4,526	–	–	0.01%	113
2025 Q3	$251K	Hold	4,526	–	–	0.02%	120
2025 Q2	$312K	Hold	4,526	–	–	0.02%	103
2025 Q1	$319K	Buy	4,526 +166	+4%	+$13.7K	0.03%	97
2024 Q4	$375K	Sell	4,360 -28	-0.6%	-$3.03K	0.03%	92
2024 Q3	$522K	Buy	4,388 +1,298	+42%	+$173K	0.04%	74
2024 Q2	$441K	Hold	3,090	–	–	0.04%	69
2024 Q1	$400K	Hold	3,090	–	–	0.04%	70
2023 Q4	$320K	Buy	+3,090	New	+$306K	0.03%	73

Other funds holding NVO

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Foster Dykema Cabot & Partners's NVO Position: Q2 2026 in Review

Foster Dykema Cabot & Partners held its Novo Nordisk (NVO) position steady in Q2 2026 at 4,526 shares worth $217K. The position accounts for 0.01% of the portfolio, ranked #117.

Foster Dykema Cabot & Partners first reported a position in NVO in Q4 2023 and has held it in 11 quarters since. The position peaked at $522K in Q3 2024. 1,353 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

Foster Dykema Cabot & Partners held 4,526 shares of Novo Nordisk worth $217K as of Q2 2026.
Foster Dykema Cabot & Partners left its Novo Nordisk share count unchanged in Q2 2026.
Novo Nordisk made up 0.01% of Foster Dykema Cabot & Partners's portfolio in Q2 2026, its #117 holding.
Foster Dykema Cabot & Partners first reported a position in Novo Nordisk in Q4 2023 and has held it in 11 quarters since.
Foster Dykema Cabot & Partners's Novo Nordisk position peaked at $522K in Q3 2024.
1,353 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Foster Dykema Cabot & Partners's 13F filing for Q2 2026, filed 11 Aug 2026.